Wall Street analyst estimates for InflaRx N.V. (IFRX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.07 | ||
| 2026-08-06 | $-0.11 | $-0.07 | -65.1% |
| 2026-05-07 | $-0.09 | $-0.17 | +47.1% |
| 2026-03-19 | $-0.17 | $-0.18 | +5.6% |
| 2025-11-10 | $-0.16 | $-0.16 | +0.0% |
| 2025-08-07 | $-0.24 | $-0.24 | +0.0% |
| 2025-05-07 | $-0.14 | $-0.18 | +22.2% |
| 2025-03-20 | $-0.09 | $-0.27 | +66.7% |
Valuation Ratios
| Price / Book | 1.38 |
| EV / EBITDA | -3.32 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $63089 | $165789 | $29331 |
| Cost of Revenue | $35658 | $66691 | $179570 | 0 | 0 | 0 | 0 | $532262 | $3.3M | $7.3M |
| Gross Profit | -$35658 | -$68420 | -$179570 | 0 | 0 | 0 | 0 | -$469173 | -$3.2M | -$7.2M |
| Research & Development | $5.3M | $14.4M | $25.0M | $44.6M | $25.7M | $35.7M | $37.5M | $41.0M | $35.4M | $25.7M |
| Selling, General & Admin | $1.8M | $5.1M | $12.8M | $12.5M | $7.9M | $11.4M | $14.3M | $16.1M | $19.3M | $17.6M |
| Operating Expenses | $6.9M | $18.8M | $37.5M | $56.8M | $33.9M | $47.6M | $32.2M | $44.1M | $49.8M | $41.0M |
| Operating Income | -$6.9M | -$19.4M | -$37.5M | -$56.8M | -$33.9M | -$47.6M | -$32.2M | -$44.6M | -$52.9M | -$48.3M |
| EBITDA | -$7.1M | -$19.6M | -$37.3M | -$56.5M | -$33.6M | -$44.9M | -$28.8M | -$42.1M | -$45.6M | -$45.2M |
| Interest Expense | $1.8M | $2.2M | 0 | $22200 | $26000 | $24769 | $45250 | $35628 | $20655 | $37690 |
| Pre-tax Income | -$8.9M | -$24.2M | -$29.8M | -$53.3M | -$34.0M | -$45.6M | -$29.5M | -$42.7M | -$46.1M | -$45.6M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $5217 | $12282 |
| Net Income | -$8.9M | -$24.2M | -$29.8M | -$53.3M | -$34.0M | -$45.6M | -$29.5M | -$42.7M | -$46.1M | -$45.6M |
| EPS | $-0.38 | $-1.03 | $-1.19 | $-1.91 | $-1.26 | $-1.10 | $-0.61 | $-0.78 | $-0.78 | $-0.66 |
| EPS (Diluted) | $-0.38 | $-1.03 | $-1.19 | $-1.91 | $-1.26 | $-1.10 | $-0.61 | $-0.78 | $-0.78 | $-0.66 |
| Shares Outstanding (Diluted) | $23.4M | $23.6M | $25.1M | $26.0M | $27.1M | $41.6M | $44.2M | $54.9M | $58.9M | $67.3M |
Price
| Price | $2.04 |
| Market Cap | $300M |
| Exchange | NASDAQ |
| Country | DE |
Related companies: ARTV · ATYR · CNTB · CNTX · IMA · KLRS · MGX
Explore sector: Healthcare · Biotechnology
More sections of IFRX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks